The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
 
David Andrew Sallman
Consulting or Advisory Role - Abbvie; Bluebird Bio; Bristol-Myers Squibb; Gilead Sciences; Intellia Therapeutics; Janssen; Kite, a Gilead company; Magenta Therapeutics; Molecular Partners; Novartis; Servier; Shattuck Labs; Syndax; Syros Pharmaceuticals; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Incyte; SERVIER
Research Funding - Aprea Therapeutics (Inst); Jazz Pharmaceuticals
 
Monzr M. Al Malki
Consulting or Advisory Role - CareDX; Gilead Sciences; Hansa Biopharma; Medexus Pharmaceuticals; NexImmune; Stemline Therapeutics
Research Funding - CareDX; Gilead Sciences; Incyte; NexImmune; Orca Bio
 
Adam Steven Asch
Research Funding - Astellas Pharma (Inst); Cartesian Therapeutics (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Juno Therapeutics (Inst); Macrogenics (Inst); MEI Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Provisional patent submitted (I)
 
Eunice S. Wang
Consulting or Advisory Role - Abbvie; Astellas Pharma; Celgene/Bristol-Myers Squibb; Genentech; Gilead Sciences; GlaxoSmithKline; Jazz Pharmaceuticals; Kite/Gilead; Novartis; Pfizer; Pharmaessentia; PTC Therapeutics; Stemline Therapeutics; Takeda
Speakers' Bureau - Astellas Pharma; dava oncology; Kite, a Gilead company; Pfizer; Stemline Therapeutics
 
Joseph G. Jurcic
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Jazz Pharmaceuticals; Novartis; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb/Celgene (Inst); Celularity (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); GlycoMimetics (Inst); PTC Therapeutics (Inst); Syros Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - Actinium Pharmaceuticals
 
Terrence J. Bradley
Consulting or Advisory Role - Abbvie; Novartis
 
Ian W. Flinn
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Century Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Great Point Partners (Inst); Hutchison MediPharma (Inst); Iksuda Therapeutics (Inst); Innocare (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CALIBR (Inst); Celgene (Inst); City of Hope (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Curis (Inst); Fate Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); MorphoSys (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TCR2 Therapeutics (Inst); Tessa Therapeutics (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
 
Daniel Aaron Pollyea
Consulting or Advisory Role - Abbvie; Agios; Amgen; Aprea Therapeutics; Astellas Pharma; Astellas Pharma; BeiGene; BerGenBio; Bristol-Myers Squibb; Celgene; Foghorn Therapeutics; Forty Seven; Genentech; Gilead Sciences; Glycomimetics; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Karyopharm Therapeutics; Kiadis Pharma; Novartis; Syndax; Syros Pharmaceuticals; Takeda
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Karyopharm Therapeutics (Inst); Teva (Inst)
 
Suman Kambhampati
No Relationships to Disclose
 
Tiffany N. Tanaka
Honoraria - OncLive
Consulting or Advisory Role - CTI BioPharma Corp
 
Joshua F. Zeidner
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Genentech; Gilead Sciences; SERVIER; Shattuck Labs; Takeda
Research Funding - Arog (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Gilead Sciences (Inst); Merck (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Agios; Celgene; Daiichi Sankyo; Dava Oncology; Forty Seven; Takeda; Tolero Pharmaceuticals
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
 
Deepa Jeyakumar
Research Funding - Jazz Pharmaceuticals; Pfizer
 
Lin Gu
Employment - Gilead Sciences
Leadership - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Anderson Tan
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Mark Chao
Employment - Forty Seven; Gilead Sciences; TenSixteen Bio
Leadership - Forty Seven; TenSixteen Bio
Stock and Other Ownership Interests - Chimera Bioengineering; Forty Seven; Gilead Sciences; Hepatx; TenSixteen Bio; TigaTx
Honoraria - D2G Oncology
Consulting or Advisory Role - Chimera Bioengineering
Patents, Royalties, Other Intellectual Property - I am an inventor on patents licensed to Hepatx Inc.; I am an inventor on several patents from Stanford University that have been licensed to Forty Seven, Inc. I am also an inventor on patents generated from Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven; Gilead Sciences; TenSixteen Bio
 
Carol Elaine O'Hear
Employment - Genentech/Roche; Gilead Sciences
Stock and Other Ownership Interests - Genentech/Roche
Patents, Royalties, Other Intellectual Property - Antibody buffering
Travel, Accommodations, Expenses - Genentech/Roche; Gilead Sciences
 
Indu Lal
Employment - Abbvie/Pharmacyclics; Gilead Sciences; The Permanente Medical Group NorCal (I)
Stock and Other Ownership Interests - Abbvie; Gilead Sciences; Reviva Pharmaceuticals (I)
 
Paresh Vyas
Honoraria - Abbvie; Astellas Pharma; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Pfizer
Research Funding - Celgene
Patents, Royalties, Other Intellectual Property - Patent for flow cytometric detection of leukaemic stem cells
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Novartis; Pfizer; SERVIER; Shattuck Labs; Syndax; Trillium Therapeutics
Research Funding - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; FATE Therapeutics; Genentech; Gilead Sciences; Glycomimetics; Hanmi; Immunogen; Novimmune; Pfizer; Servier; Trillium Therapeutics; Trovagene